Search: Aurora

Why Aurora Cannabis Stock Popped Today

Shares of marijuana company Aurora Cannabis (NASDAQ: ACB) jumped 3% as of 3 p.m. ET on Monday. You can thank its competitor Tilray (NASDAQ: TLRY) for that. In a surprise announcement this morning, Tilray said it was able to cut so much cost from its reverse merger with Aphria last year that it ended up earning $6 million in its…

Aurora Cannabis Delivers ~$10 Million Shipment of Medical Cannabis to Israel

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth approximately C$10 million – the company’s largest ever shipment to Israel, and what is believed to be the largest export of medical Cannabis into the Israeli market. Delivered in December, the…

Aurora Cannabis Announces New Director and Updates to The Board

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the appointment of Chitwant Kohli to the Company’s Board of Directors (the “Board”), effective today. This is a newly added position that expands the Board to nine members, seven of whom are independent. READ MORE: https://finance.yahoo.com/news/aurora-cannabis-announces-director-updates-115000454.html?.tsrc=rss

Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”), the Canadian company defining the future of cannabinoids worldwide, together with 22nd Century Group, Inc. (NASDAQ: XXII) (“22nd Century”) announced today a three-way non-exclusive agreement to license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), intended to…

Is This Pot Stock Repeating Aurora Cannabis’ Mistakes?

The Canadian industry, in particular, has faced several headwinds since it legalized medical and recreational cannabis. Fast forward to the present day, now both of these cannabis growers are struggling to generate enough revenue to achieve positive earnings before interest, tax, depreciation, and amortization (EBITDA). While investors believed Canopy could rebound this year, its second-quarter earnings tell a different story.…